This report provides the recent approval of a number of highly effective drugs, including Zytiga and Xtandi, has provided late-stage patients with a number of options and increased survival times by a number of months.
Complete report of 107 Pages is available @ http://www.reportsnreports.com/reports/270793-prostate-cancer-therapeutics-market-to-2019-rising-prevalence-and-strong-uptake-of-recent-approvals-to-drive-robust-growth-to-2019.html .
These recent approvals are anticipated to generate strong revenues during the forecast following increasing uptake by physicians as the treatment algorithm shifts towards their first-line usage over Taxotere. Additionally, a very large late-stage pipeline is anticipated to produce a number of new market entrants which are superior to existing products. Overall, this is anticipated to drive rapid market growth from $4.1 billion in 2012 to $8.0 billion by 2019 at a CAGR of 10.1%.
